Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Mereo BioPharma Group in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.08) for the year. Cantor Fitzgerald has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share.
Several other analysts have also issued reports on the stock. Needham & Company LLC restated a "buy" rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Tuesday, May 13th. JPMorgan Chase & Co. began coverage on shares of Mereo BioPharma Group in a report on Thursday, March 27th. They issued an "overweight" rating and a $7.00 price objective on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of "Buy" and an average target price of $7.67.
Read Our Latest Report on Mereo BioPharma Group
Mereo BioPharma Group Trading Down 0.7%
MREO traded down $0.02 on Wednesday, hitting $2.76. The company had a trading volume of 1,235,452 shares, compared to its average volume of 1,099,907. The firm has a market cap of $438.84 million, a P/E ratio of -39.43 and a beta of 0.47. Mereo BioPharma Group has a 1 year low of $1.58 and a 1 year high of $5.02. The company's fifty day moving average price is $2.36 and its 200 day moving average price is $2.77.
Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01).
Institutional Trading of Mereo BioPharma Group
A number of institutional investors and hedge funds have recently bought and sold shares of MREO. Newbridge Financial Services Group Inc. purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $37,000. HealthInvest Partners AB increased its stake in Mereo BioPharma Group by 95.0% during the fourth quarter. HealthInvest Partners AB now owns 390,000 shares of the company's stock worth $1,373,000 after purchasing an additional 190,000 shares during the period. Sheets Smith Investment Management purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $59,000. XTX Topco Ltd purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $133,000. Finally, Walleye Capital LLC purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $454,000. 62.83% of the stock is currently owned by hedge funds and other institutional investors.
About Mereo BioPharma Group
(
Get Free Report)
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Featured Stories
Before you consider Mereo BioPharma Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mereo BioPharma Group wasn't on the list.
While Mereo BioPharma Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.